Sector
PharmaceuticalsOpen
₹37Prev. Close
₹39.99Turnover(Lac.)
₹0.03Day's High
₹37.05Day's Low
₹3752 Week's High
₹58.3952 Week's Low
₹35.1Book Value
₹1.68Face Value
₹1Mkt Cap (₹ Cr.)
175.29P/E
20.1EPS
1.99Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 4.73 | 4.73 | 4.73 | 4.73 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -4.4 | 0.73 | 10.16 | 13.71 |
Net Worth | 0.33 | 5.46 | 14.89 | 18.44 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Revenue | 132.71 | 106.28 | 1.46 | 0.19 |
yoy growth (%) | 24.86 | 7,179.88 | 660 | -89 |
Raw materials | -96.85 | -80.24 | -0.35 | -0.08 |
As % of sales | 72.97 | 75.5 | 24.24 | 42.54 |
Employee costs | -14.09 | -10.8 | -0.83 | -2.13 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Profit before tax | 5.53 | 1.22 | -1 | -4.04 |
Depreciation | -1.91 | -1.66 | -0.34 | -0.29 |
Tax paid | -0.43 | 0.15 | 0.07 | 0 |
Working capital | 5.9 | 31.91 | -0.32 | 1.93 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 24.86 | 7,179.88 | 660 | -89 |
Op profit growth | 88.23 | -553.78 | -70.97 | 76.22 |
EBIT growth | 137.67 | -609.74 | -78.87 | 110.41 |
Net profit growth | 269.61 | -248.57 | -77.06 | 138.02 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,766.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,958.35 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.75 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,434.1 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
CMD & CEO
Sameer Goel
Independent Director
Jagdeep Dhavvan
Independent Director
Richa Gupta
Non Executive Director
Vipul Goel
Company Sec. & Compli. Officer
Pallavi Garg
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Kimia Biosciences Ltd
Summary
Kimia Bio-sciences Limited (Formerly known Laurel Organics Limited) was incorporated in September, 1993 led by the Promoters, A K Bansal, K S Varma, Atul Sharma, A P Godiyal, D K Gupta and R K Bansal. The Company has own manufacturing of Bulk Drugs-APIs at its plant located at Gurgaon, Haryana. The Company is engaged into the business of Pharamaceutical products.The company set up a bulk drug manufacturing unit at Gurgaon, Haryana, at a project cost of Rs 10.41 cr. It came out with a public issue in Feb.95 to part-finance the project. Commercial production commenced in May 95. During the 1998-99, the company has become a sick industrial units.The Honble BIFR vide order dated 27th December, 2005 had deregistered the Company as Sick Industrial Undertaking on the ground that 100% of the capacity was utilized for manufacture of the intermediate products for M/s Ranbaxy Laboratoty Limfted (RLL) and , thereby, turning-out to be an ancillary industrial Undertaking. .The Honble AAIFR disposed the appeal of M/s Ranbaxy Lab. Ltd vide its Order dated 30.08.2006, directing them to file an application before the Hoble BIFR only to redress grievances. Therefore, M/s Ranbaxy Lab. Ltd had filed an application-dated 31.10.06 before the Honble BIFR, requesting them to consider issuance of appropriate corrective orders. The Board has re-confirmed its earlier order. Therefore, despite negative net worth, the Company is out of BIFR purview.During the year 2017-18, the Scheme of Arrangement for Am
Read More
The Kimia Biosciences Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹37.05 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kimia Biosciences Ltd is ₹175.29 Cr. as of 09 May ‘25
The PE and PB ratios of Kimia Biosciences Ltd is 20.1 and 23.79 as of 09 May ‘25
The 52-week high/low is the highest and lowest price at which a Kimia Biosciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Kimia Biosciences Ltd is ₹35.1 and ₹58.39 as of 09 May ‘25
Kimia Biosciences Ltd's CAGR for 5 Years at 10.16%, 3 Years at 3.37%, 1 Year at -16.95%, 6 Month at -19.68%, 3 Month at -15.38% and 1 Month at -1.82%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.